Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

CNBC's Becky Quick reports on the progress of KJ Muldoon, the first patient to receive a personalized CRISPR-based gene ...

CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these ...

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

Intellia TherapeuticsNTLA stock shot higher Tuesday after the Food and Drug Administration said it would allow the company to restart a study of its gene-editing drug in patients with polyneuropathy.

Nvidia, the chipmaker at the center of the AI boom, just released its quarterly results. Follow our live coverage here.

Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in ...